Veeva’s Economic Moats
- Imagine a pharma company trying to change platforms…
- Data migration from old to new. Carries risks. May be time consuming. Interrupt workflow.
- Customization of the new solution to the business.
- Training of staff.
- This is both expensive and risky. Meaning once a pharma business has installed Veeva into their business, they need extremely compelling reasons to change it.
- Here’s the best part: 19 of the 20 top LS businesses have installed Veeva. Notable customers include Pfizer, Novartis, Merck, Bayer, Gilead.
- VEEV software solutions are deeply (and increasingly) embedded into customer systems.
- High retention, continued development of new applications, increasing penetration within existing customers.
- High financial cost and learning curve to switch vendors. Risking unplanned downtime, a system breach, or data loss. Can prove catastrophic.
- Increased number of touch points within an organization reinforces switch costs.
Intangible Assets – Brand
- Veeva brand embodies High-Level Domain Expertise, providing world-class software solutions and customer service.
Conclusion – Price Implied Expectations (Apr 2020)
Given a TAM estimate of $12bn, the current market cap of VEEV implies that sales will grow to ~$7bn by 2029.
For the full report, see link below